Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician’s perspective

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. (WA) DC: American Psychiatric Association; 2013.
   Google Scholar
• Akosile W, Colquhoun D, Young R, et al. The association between post-traumatic stress disorder and coronary artery disease: a meta-analysis. Australas Psychiatry. 2018 Oct;26(5):524–530. doi: 10.1177/1039856218789779
   PubMed Web of Science ®Google Scholar
• Benjet C, Bromet E, Karam EG, et al. The epidemiology of traumatic event exposure worldwide: results from the world mental health survey consortium. Psychol Med. 2016 Oct 29;46(2):327–343. doi: 10.1017/S0033291715001981
   PubMed Web of Science ®Google Scholar
• Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry. 2000;61(Suppl 5): 4–12. discussion 13-4.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. Trauma and PTSD in the WHO world mental health surveys. Eur J Psychotraumatol. 2017 Oct 27;8(sup5):1353383. doi: 10.1080/20008198.2017.1353383
   PubMed Web of Science ®Google Scholar
• Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry. 1995;52(12):1048–1060. doi: 10.1001/archpsyc.1995.03950240066012
   PubMed Web of Science ®Google Scholar
• Koenen KC, Ratanatharathorn A, Ng L, et al. Posttraumatic stress disorder in the world mental health surveys. Psychol Med. 2017;47(13):2260–2274. doi: 10.1017/S0033291717000708
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. National survey of mental health and wellbeing. Australian Bureau of Statistics; 2007.
   Google Scholar
• Lohmann S, Cowlishaw S, Ney L, et al. The trauma and mental health impacts of coercive control: a systematic review and meta-analysis. Trauma Violence Abuse. 2023;15248380231162972.
   Web of Science ®Google Scholar
• Akosile W, Young R, Lawford B, et al. PTSD symptoms associated with myocardial infarction: practical clinical implications. Australas Psychiatry. 2018 Feb;26(1):60–64. doi: 10.1177/1039856217734738
   PubMed Web of Science ®Google Scholar
• Hoskins M, Pearce J, Bethell A, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2015 Feb;206(2):93–100. doi: 10.1192/bjp.bp.114.148551
   PubMed Web of Science ®Google Scholar
• Watts BV, Schnurr PP, Mayo L, et al. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013 Jun;74(6):e541–50. doi: 10.4088/JCP.12r08225
   PubMed Web of Science ®Google Scholar
• Merz J, Schwarzer G, Gerger H. Comparative efficacy and acceptability of pharmacological, psychotherapeutic, and combination treatments in adults with posttraumatic stress disorder: a network meta-analysis. JAMA Psychiatry. 2019 Sep 1;76(9):904–913. doi: 10.1001/jamapsychiatry.2019.0951
   PubMed Web of Science ®Google Scholar
• Watkins LE, Sprang KR, Rothbaum BO. Treating PTSD: a review of evidence-based psychotherapy interventions. Front Behav Neurosci. 2018;12:258. doi: 10.3389/fnbeh.2018.00258
   PubMed Web of Science ®Google Scholar
• Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013 Dec;13(12):CD003388. doi: 10.1002/14651858.CD003388.pub4
   Google Scholar
• Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012 Jul;15(6):825–840. doi: 10.1017/S1461145711001209
   PubMed Web of Science ®Google Scholar
• Singewald N, Schmuckermair C, Whittle N, et al. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther. 2015 May;149:150–190.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006 Jan;25(1):CD002795. doi: 10.1002/14651858.CD002795.pub2
   Google Scholar
• Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex Pharmacology. Physiol Rev. 2016 Oct;96(4):1593–1659. doi: 10.1152/physrev.00002.2016
   PubMed Web of Science ®Google Scholar
• Bahji A, Stephenson C. International perspectives on the implications of cannabis legalization: a systematic review & thematic analysis. Int J Environ Res Public Health. 2019;16(17):3095. doi: 10.3390/ijerph16173095
   PubMed Web of Science ®Google Scholar
• Sznitman SR, Bretteville-Jensen AL. Public opinion and medical cannabis policies: examining the role of underlying beliefs and national medical cannabis policies.Harm Reduct J. 2015 2015 Oct 14;12(1):46. doi: 10.1186/s12954-015-0082-x
   PubMedGoogle Scholar
• Australian Government. Narcotic Drugs amendment act, No.12. In: legislation FRo, editor. 2016.
   Google Scholar
• Therapeutic Goods Administration. Medicinal Cannabis - guidance documents. 2018.
   Google Scholar
• Therapeutic Goods Administration. Access to medicinal cannabis products. 2019.
   Google Scholar
• Clarke RC, Merlin MD. Cannabis domestication, breeding history, present-day genetic diversity, and future prospects.Crit Rev Plant Sci. 2016 2016 Nov 1;35(5–6):293–327. doi: 10.1080/07352689.2016.1267498
   Web of Science ®Google Scholar
• Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005 Dec 22;78(5):539–548. doi: 10.1016/j.lfs.2005.09.011
   PubMed Web of Science ®Google Scholar
• Oultram JMJ, Pegler JL, Bowser TA, et al. Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC. Biomedicines. 2021;9(3):234. doi: 10.3390/biomedicines9030234
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Gaoni Y. A total synthesis of dl-Δ1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc. 1965;87(14):3273–3275. doi: 10.1021/ja01092a065
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(S1):11S–19S. doi: 10.1002/j.1552-4604.2002.tb05998.x
   PubMedGoogle Scholar
• Alves P, Amaral C, Teixeira N, et al. Cannabis sativa: much more beyond Δ9-tetrahydrocannabinol. Pharmacol Res. 2020 2020 Jul 1;157:104822.
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RH, Crippa JA, et al. Safety and side effects of Cannabidiol, a cannabis sativa constituent Current drug safety. 2011;6(4):237–249. doi: 10.2174/157488611798280924
   Google Scholar
• Campos AC, Fogaca MV, Sonego AB, et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016 Oct;112:119–127.
   PubMed Web of Science ®Google Scholar
• Caprioglio D, Amin HIM, Taglialatela-Scafati O, et al. Minor phytocannabinoids: a misleading name but a promising opportunity for biomedical research. Biomolecules. 2022;12(8):1084. doi: 10.3390/biom12081084
   PubMed Web of Science ®Google Scholar
• Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.British J Pharmacology. 2011 2011 Aug 1;163(7):1344–1364. doi: 10.1111/j.1476-5381.2011.01238.x
   PubMed Web of Science ®Google Scholar
• Walsh KB, McKinney AE, Holmes AE. Minor cannabinoids: biosynthesis, molecular Pharmacology and potential therapeutic uses [review]. Front Pharmacol. 2021 2021 No 29;12:12. doi: 10.3389/fphar.2021.777804
   Web of Science ®Google Scholar
• Booth JK, Bohlmann J. Terpenes in Cannabis sativa – From plant genome to humans. Plant Sci. 2019 2019 Juy 1;284:67–72. doi: 10.1016/j.plantsci.2019.03.022
   PubMed Web of Science ®Google Scholar
• Pollastro F, Minassi A, Fresu LG. Cannabis phenolics and their bioactivities. Curr Med Chem. 2018;25(10):1160–1185. doi: 10.2174/0929867324666170810164636
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids.Clin Pharmacokinet. 2003 2003 Apr 1;42(4):327–360. doi: 10.2165/00003088-200342040-00003.
   PubMed Web of Science ®Google Scholar
• Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 2019 2019 Dec 1;30:98–102. doi: 10.1016/j.copsyc.2019.04.002
   PubMed Web of Science ®Google Scholar
• O’Brien K, Blair P. Routes of administration, pharmacokinetics and safety of medicinal cannabis. In: O’Brien K Blair P, editors Medicinal cannabis and CBD in mental healthcare. Cham: Springer International Publishing; 2021. p. 513–557.
   Google Scholar
• Eichler M, Spinedi L, Unfer-Grauwiler S, et al. Heat exposure of cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012 May;78(7):686–691. doi: 10.1055/s-0031-1298334
   PubMed Web of Science ®Google Scholar
• Loflin M, Earleywine M. No smoke, no fire: what the initial literature suggests regarding vapourized cannabis and respiratory risk. Can J Respir Ther. 2015;51(1):7–9. Winter. doi: 10.1111/add.12508
   PubMedGoogle Scholar
• Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018 Nov;84(11):2477–2482. doi: 10.1111/bcp.13710
   PubMed Web of Science ®Google Scholar
• Zamarripa CA, Vandrey R, Spindle TR. Factors that impact the Pharmacokinetic and pharmacodynamic effects of cannabis: a review of human laboratory studies.Curr Addict Rep. 2022 2022 Dec 1;9(4):608–621. doi: 10.1007/s40429-022-00429-4
   Google Scholar
• Vandrey R, Herrmann ES, Mitchell JM, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol. 2017 Mar 1;41(2):83–99. doi: 10.1093/jat/bkx012
   PubMed Web of Science ®Google Scholar
• Newmeyer MN, Swortwood MJ, Barnes AJ, et al. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem. 2016 Dec;62(12):1579–1592. doi: 10.1373/clinchem.2016.263475
   PubMed Web of Science ®Google Scholar
• Spindle TR, Cone EJ, Herrmann ES, et al. Pharmacokinetics of cannabis brownies: a controlled examination of Δ9-tetrahydrocannabinol and metabolites in blood and oral fluid of healthy adult males and females. J Anal Toxicol. 2020;44(7):661–671. doi: 10.1093/jat/bkaa067
   PubMed Web of Science ®Google Scholar
• Franco V, Gershkovich P, Perucca E, et al. The interplay between liver first-pass effect and lymphatic absorption of Cannabidiol and its implications for Cannabidiol oral formulations. Clin Pharmacokinet. 2020 2020 Dec 1;59(12):1493–1500. doi: 10.1007/s40262-020-00931-w
   PubMed Web of Science ®Google Scholar
• Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based Medicine extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based Medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther. 2004 2004 Jan 5;3(3):35–77.
   Google Scholar
• Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers [doi: 10.1111/bcp.14617]. Br J Clin Pharmacol. 2020 Oct 19;87:2070–2077.
   PubMed Web of Science ®Google Scholar
• Scholfield CN, Waranuch N, Kongkaew C. Systematic review on transdermal/topical Cannabidiol trials: a reconsidered way forward. Cannabis Cannabinoid Res. 2022;8(4):589–602. doi: 10.1089/can.2021.0154
   PubMedGoogle Scholar
• Tijani AO, Thakur D, Mishra D, et al. Delivering therapeutic cannabinoids via skin: Current state and future perspectives. J Control Release. 2021 Jun 10;334:427–451. doi: 10.1016/j.jconrel.2021.05.005
   PubMed Web of Science ®Google Scholar
• Kebede L, Masoomi Dezfooli S, Seyfoddin A. Medicinal cannabis pharmacokinetics and potential methods of delivery.Pharm Dev Technol. 2022 2022 Feb 7;27(2):202–214. doi: 10.1080/10837450.2022.2035748
   PubMed Web of Science ®Google Scholar
• ElSohly Mahmoud A, Gul W, Walker Larry A. Pharmacokinetics and tolerability of Δ9-THC-Hemisuccinate in a suppository formulation as an alternative to capsules for the systemic delivery of Δ9-THC. Med Cannabis Cannabinoids. 2018;1(1):44–53. doi: 10.1159/000489037
   PubMedGoogle Scholar
• Ney LJ, Crombie KM, Mayo LM, et al. Translation of animal endocannabinoid models of PTSD mechanisms to humans: where to next? Neuroscience & Biobehavioral Reviews. 2022 2022 Jan 1;132:76–91.
   PubMed Web of Science ®Google Scholar
• Mayo LM, Rabinak CA, Hill MN, et al. Targeting the endocannabinoid system in the treatment of PTSD: a promising case of preclinical-clinical translation? Biological Psychiatry. 2021 2021 Jul 24;91(3):262–272. doi: 10.1016/j.biopsych.2021.07.019
   PubMed Web of Science ®Google Scholar
• Hill MN, Campolongo P, Yehuda R, et al. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology. 2018 Jul 26;43(1):80–102. doi: 10.1038/npp.2017.162
   PubMed Web of Science ®Google Scholar
• Korem N, Zer-Aviv TM, Ganon-Elazar E, et al. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):193–202. doi: 10.1515/jbcpp-2015-0058
   PubMedGoogle Scholar
• Lookfong NA, Raup-Konsavage WM, Silberman Y. Potential utility of Cannabidiol in stress-related disorders.Cannabis Cannabinoid Res. 2022 2023 Apr 1;8(2):230–240. doi: 10.1089/can.2022.0130
   PubMedGoogle Scholar
• Orsolini L, Chiappini S, Volpe U, et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina (Kaunas). 2019;55(9):525. doi: 10.3390/medicina55090525
   PubMed Web of Science ®Google Scholar
• Steenkamp MM, Blessing EM, Galatzer-Levy IR, et al. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017 Mar;34(3):207–216. doi: 10.1002/da.22596
   PubMed Web of Science ®Google Scholar
• Zer-Aviv TM, Segev A, Akirav I. Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. Behav Pharmacol. 2016 Oct;27(7):561–569. doi: 10.1097/FBP.0000000000000253
   PubMed Web of Science ®Google Scholar
• White CM. A review of human studies assessing Cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol. 2019 Jul;59(7):923–934. doi: 10.1002/jcph.1387
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456–2473. doi: 10.1001/jama.2015.6358
   PubMed Web of Science ®Google Scholar
• Scherma M, Muntoni AL, Riedel G, et al. Cannabinoids and their therapeutic applications in mental disorders Dialogues Clin Neurosci. Dialogues Clin Neurosci. 2020 Sep;22(3):271–279. doi: 10.31887/DCNS.2020.22.3/pfadda
   PubMed Web of Science ®Google Scholar
• Hasbi A, Madras BK, George SR. Endocannabinoid system and exogenous cannabinoids in depression and anxiety: a review. Brain Sci. 2023 Feb 14;13(2):325. doi: 10.3390/brainsci13020325
   PubMed Web of Science ®Google Scholar
• Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010. doi: 10.1016/S2215-0366(19)30401-8
   PubMed Web of Science ®Google Scholar
• Balsevich G, Petrie GN, Hill MN. Endocannabinoids: Effectors of glucocorticoid signaling. Front Neuroendocrinol. 2017 Jul 21;47:86–108. doi: 10.1016/j.yfrne.2017.07.005
   PubMed Web of Science ®Google Scholar
• Morena M, Patel S, Bains JS, et al. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016 Jan;41(1):80–102. doi: 10.1038/npp.2015.166
   PubMed Web of Science ®Google Scholar
• Ney LJ, Matthews A, Bruno R, et al. Modulation of the endocannabinoid system by sex hormones: implications for posttraumatic stress disorder. Neurosci Biobehav Rev. 2018;94:302–320. doi: 10.1016/j.neubiorev.2018.07.006
   PubMed Web of Science ®Google Scholar
• Mayo LM, Asratian A, Lindé J, et al. Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice. Mol Psychiatry. 2020 May;25(5):993–1005. doi: 10.1038/s41380-018-0215-1
   PubMed Web of Science ®Google Scholar
• Mayo LM, Asratian A, Lindé J, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental Medicine trial. Biological Psychiatry. 2020;87(6):538–547. doi: 10.1016/j.biopsych.2019.07.034
   PubMed Web of Science ®Google Scholar
• Ney LJ, Matthews A, Hsu CK, et al. Cannabinoid polymorphisms interact with plasma endocannabinoid levels to predict fear extinction learning. Depress Anxiety. 2021 Jun 20;38(10):1087–1099. doi: 10.1002/da.23170
   PubMed Web of Science ®Google Scholar
• Rehman Y, Saini A, Huang S, et al. Cannabis in the management of PTSD: a systematic review. AIMS Neurosci. 2021;8(3):414–434. doi: 10.3934/Neuroscience.2021022
   PubMed Web of Science ®Google Scholar
• Bouton ME, Maren S, McNally GP. Behavioral and neurobiological mechanisms of Pavlovian and instrumental extinction learning.Physiol Rev. 2020 2021 Apr 1;101(2):611–681. doi: 10.1152/physrev.00016.2020
   PubMed Web of Science ®Google Scholar
• Zuj DV, Palmer MA, Lommen MJ, et al. The centrality of fear extinction in linking risk factors to PTSD: a narrative review. Neurosci Biobehav Rev. 2016 Oct;69:15–35.
   PubMed Web of Science ®Google Scholar
• Sharpe L, Sinclair J, Kramer A, et al. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020 2020 Oct 2;18(1):374. doi: 10.1186/s12967-020-02518-2
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014 Mar 1;136:162–165. doi: 10.1016/j.drugalcdep.2013.12.008
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Vujanovic AA, Drescher KD. Cannabis use among military veterans after residential treatment for posttraumatic stress disorder. Psychol Addict Behav. 2011 Sep;25(3):485–491. doi: 10.1037/a0021945
   PubMed Web of Science ®Google Scholar
• Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico medical cannabis program. J Psychoactive Drugs. 2014 Jan;46(1):73–77. doi: 10.1080/02791072.2013.873843
   PubMed Web of Science ®Google Scholar
• Rup J, Freeman TP, Perlman C, et al. Cannabis and mental health: prevalence of use and modes of cannabis administration by mental health status. Add Behav. 2021 2021 May 19;106991. doi: 10.1016/j.addbeh.2021.106991
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Brunstetter M, Simonian A, et al. The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder. Cannabis Cannabinoid Res. 2020;7(2): 214–223. doi: 10.1089/can.2020.0056
   PubMedGoogle Scholar
• LaFrance EM, Glodosky NC, Bonn-Miller M, et al. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affective Disorders. 2020 2020 Sep 1;274:298–304.
   PubMed Web of Science ®Google Scholar
• Drost L, Wan B, Chan S, et al. Efficacy of different varieties of medical cannabis in relieving symptoms in post-traumatic stress disorder (PTSD) patients. J Pain Manag. 2017 Feb 01;10(3): 415–422.
   Google Scholar
• Australian Government. Response to ABC - Cannabis as a treatment for PTSD. Affairs DoV, editor. Department of Veterans Affairs; 2020. https://www.dva.gov.au/newsroom/media-centre/record/response-abc-cannabis-treatment-ptsd#:~:text=A%202017%20report%20prepared%20for,PTSD%2C%20depression%20or%20anxiety%20disorders
   Google Scholar
• Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015 Jan;51:585–588.
   PubMed Web of Science ®Google Scholar
• Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014 Oct;34(5):559–564. doi: 10.1097/JCP.0000000000000180
   PubMed Web of Science ®Google Scholar
• Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009 Winter;15(1):84–88. doi: 10.1111/j.1755-5949.2008.00071.x
   PubMed Web of Science ®Google Scholar
• Smith P, Chan S, Blake A, et al. Medical cannabis use in military and police veterans diagnosed with post-traumatic stress disorder (PTSD). Journal of Pain Management. 2017 Feb 01;10:p. 397–405.
   Google Scholar
• Passie T, Emrich HM, Karst M, et al. Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012 Jul;4(7–8):649–659. doi: 10.1002/dta.1377
   PubMed Web of Science ®Google Scholar
• Elms L, Shannon S, Hughes S, et al. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2018 Dec 13;25(4):392–397. doi: 10.1089/acm.2018.0437
   PubMed Web of Science ®Google Scholar
• Shannon S, Lewis N, Lee H, et al. Cannabidiol in anxiety and sleep: a Large case series. Perm J. 2019;23(1):18–041. doi: 10.7812/TPP/18-041
   PubMedGoogle Scholar
• Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016 Fall;20(4):108–111. doi: 10.7812/TPP/16-005
   PubMedGoogle Scholar
• Hauer D, Schelling G, Gola H, et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One. 2013;8(5):e62741. doi: 10.1371/journal.pone.0062741
   PubMed Web of Science ®Google Scholar
• Wilker S, Pfeiffer A, Elbert T, et al. Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology. 2016 May;67:198–206.
   PubMed Web of Science ®Google Scholar
• Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology. 2013 Dec;38(12):2952–2961. doi: 10.1016/j.psyneuen.2013.08.004
   PubMed Web of Science ®Google Scholar
• Ney LJ, Matthews A, Bruno R, et al. Cannabinoid interventions for PTSD: where to next? Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:124–140. doi: 10.1016/j.pnpbp.2019.03.017
   PubMed Web of Science ®Google Scholar
• Metrik J, Stevens AK, Gunn RL, et al. Cannabis use and posttraumatic stress disorder: prospective evidence from a longitudinal study of veterans. Psychol Med. 2022;52(3):446–456. doi: 10.1017/S003329172000197X
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015 Sep;76(9):1174–1180. doi: 10.4088/JCP.14m09475
   PubMed Web of Science ®Google Scholar
• Livingston NA, Farmer SL, Mahoney CT, et al. Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychol Addict Behav. 2022 Mar;36(2):131–143. doi: 10.1037/adb0000736
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Pierce JD, Mavandadi S, et al. Mental health symptom severity in cannabis using and non-using veterans with probable PTSD. J Affective Disorders. 2016;190:439–442. doi: 10.1016/j.jad.2015.10.048
   PubMed Web of Science ®Google Scholar
• Bedard-Gilligan M, Garcia N, Zoellner LA, et al. Alcohol, cannabis, and other drug use: engagement and outcome in PTSD treatment. Psychol Addict Behav. 2018 May;32(3):277–288. doi: 10.1037/adb0000355
   PubMed Web of Science ®Google Scholar
• Hill ML, Loflin M, Nichter B, et al. Cannabis use among U.S. military veterans with subthreshold or threshold posttraumatic stress disorder: psychiatric comorbidities, functioning, and strategies for coping with posttraumatic stress symptoms. J Trauma Stress. 2022 Aug;35(4):1154–1166. doi: 10.1002/jts.22823
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS One. 2021;16(3):e0246990. doi: 10.1371/journal.pone.0246990
   PubMed Web of Science ®Google Scholar
• Foa EB, Hembree EA, Rothbaum BO, et al. Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences: therapist guide. 2nd ed. (Prolonged exposure therapy for PTSD: Emotional processing of traumatic experiences: Therapist guide, 2nd ed.). (NY) NY US: Oxford University Press; 2019.
   Google Scholar
• Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychological Bulletin. 1986;99(1):20–35. doi: 10.1037/0033-2909.99.1.20
   PubMed Web of Science ®Google Scholar
• Scheveneels S, Boddez Y, Vervliet B, et al. The validity of laboratory-based treatment research: bridging the gap between fear extinction and exposure treatment. Behav Res Ther. 2016 Nov;86:87–94.
   PubMed Web of Science ®Google Scholar
• Scheveneels S, Boddez Y, Hermans D. Predicting clinical outcomes via human fear conditioning: a narrative review. Behav Res Ther. 2021 2021 Jul 1;142:103870. doi: 10.1016/j.brat.2021.103870
   PubMed Web of Science ®Google Scholar
• Graham BM, Milad MR. The study of fear extinction: implications for anxiety disorders.Am J Psychiatry. 2011 2011 Dec 1;168(12):1255–1265. doi: 10.1176/appi.ajp.2011.11040557
   PubMed Web of Science ®Google Scholar
• Ney LJ, Crombie KM, Mayo LM. Chapter 5 - the endocannabinoid system and posttraumatic stress disorder (PTSD): a new narrative. In: Patel V, Preedy V, and Martin C, editors Neurobiology and physiology of the endocannabinoid system. Academic Press; 2023. p. 67–79. doi: 10.1016/B978-0-323-90877-1.00013-9
   Google Scholar
• Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–534. doi: 10.1038/nature00839
   PubMed Web of Science ®Google Scholar
• Akirav I. The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci. 2011;5:34. doi: 10.3389/fnbeh.2011.00034
   PubMed Web of Science ®Google Scholar
• Chhatwal JP, Davis M, Maguschak KA, et al. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology. 2005 Mar;30(3):516–524. doi: 10.1038/sj.npp.1300655
   PubMed Web of Science ®Google Scholar
• Ney LJ, Akhurst J, Bruno R, et al. Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD. Prog Neuro Psychopharmacol Biol Psychiatry. 2021 2021 Mar 8;105:110118.
   PubMed Web of Science ®Google Scholar
• Bowers ME, Ressler KJ. Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention. Neuropsychopharmacology. 2015 Feb;40(3):688–700. doi: 10.1038/npp.2014.225
   PubMed Web of Science ®Google Scholar
• Gunduz-Cinar O, MacPherson KP, Cinar R, et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry. 2013 Jul;18(7):813–823. doi: 10.1038/mp.2012.72
   PubMed Web of Science ®Google Scholar
• Jenniches I, Ternes S, Albayram O, et al. Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol Psychiatry. 2016 May 15;79(10):858–868. doi: 10.1016/j.biopsych.2015.03.033
   PubMed Web of Science ®Google Scholar
• Laricchiuta D, Centonze D, Petrosini L. Effects of endocannabinoid and endovanilloid systems on aversive memory extinction. Behav Brain Res. 2013 Nov 1;256:101–107. doi: 10.1016/j.bbr.2013.08.010
   PubMed Web of Science ®Google Scholar
• Ghasemi M, Abrari K, Goudarzi I, et al. Effect of WIN55-212-2 and consequences of extinction training on conditioned fear memory in PTSD male rats. Basic Clin Neurosci. 2017;8(6):493–502. doi: 10.29252/nirp.bcn.8.6.493
   PubMedGoogle Scholar
• Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol. 2007 Aug;36(1):92–101. doi: 10.1007/s12035-007-8004-x
   PubMed Web of Science ®Google Scholar
• Smiley CE, Saleh HK, Nimchuk KE, et al. Adolescent exposure to delta-9-tetrahydrocannabinol and ethanol heightens sensitivity to fear stimuli. Behav Brain Res. 2021 Oct 11;415:113517. doi: 10.1016/j.bbr.2021.113517
   PubMed Web of Science ®Google Scholar
• Balogh Z, Szente L, Biro L, et al. Endocannabinoid interactions in the regulation of acquisition of contextual conditioned fear. Prog Neuro Psychopharmacol Biol Psychiatry. 2019 2019 Mar 2;90:84–91.
   PubMed Web of Science ®Google Scholar
• Weisser S, Mueller M, Rauh J, et al. Acquisition of threat responses are associated with elevated plasma concentration of endocannabinoids in male humans. Neuropsychopharmacology. 2022 2022 Oct 1;47(11):1931–1938. doi: 10.1038/s41386-022-01320-6
   PubMed Web of Science ®Google Scholar
• Ney LJ, Cooper J, Lam GN, et al. Hair endocannabinoids predict physiological fear conditioning and salivary endocannabinoids predict subjective stress reactivity in humans. Psychoneuroendocrinology. 2023 2023 Aug 1;154:106296.
   PubMed Web of Science ®Google Scholar
• Ney LJ, Nichols DS, Lipp OV. Fear conditioning depends on the nature of the unconditional stimulus and may be related to hair levels of endocannabinoids [doi: 10.1111/psyp.14297].Psychophysiology. 2023 2023 Mar 23;60(8):e14297. doi: 10.1111/psyp.14297
   PubMed Web of Science ®Google Scholar
• Zabik NL, Iadipaolo AS, Marusak HA, et al. A common genetic variant in fatty acid amide hydrolase is linked to alterations in fear extinction neural circuitry in a racially diverse, nonclinical sample of adults. J Neurosci Res. 2021 2021 Mar 29;100(3):744–761. doi: 10.1002/jnr.24860
   PubMed Web of Science ®Google Scholar
• Zabik NL, Rabinak CA, Peters CA, et al. Cannabinoid modulation of corticolimbic activation during extinction learning and fear renewal in adults with posttraumatic stress disorder. Neurobiol Learn Mem. 2023 2023 May 1;201:107758.
   PubMed Web of Science ®Google Scholar
• Crombie KM, Privratsky AA, Schomaker CM, et al. The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD. NeuroImage Clin. 2022 2022 Jan 1;33:102922.
   PubMed Web of Science ®Google Scholar
• Crombie KM, Sartin-Tarm A, Sellnow K, et al. Exercise-induced increases in anandamide and BDNF during extinction consolidation contribute to reduced threat following reinstatement: preliminary evidence from a randomized controlled trial. Psychoneuroendocrinology. 2021 2021 Jul 9;132:105355.
   PubMed Web of Science ®Google Scholar
• Heitland I, Klumpers F, Oosting RS, et al. Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1. Transl Psychiatry. 2012 Sep 25;2(9):e162. doi: 10.1038/tp.2012.90
   PubMedGoogle Scholar
• Hammoud MZ, Peters C, Hatfield JRB, et al. Influence of Δ9-tetrahydrocannabinol on long-term neural correlates of threat extinction memory retention in humans. Neuropsychopharmacol. 2019 2019 Sep 1;44(10):1769–1777. doi: 10.1038/s41386-019-0416-6
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Angstadt M, Lyons M, et al. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem. 2014 Sep;113:125–134.
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Angstadt M, Sripada CS, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology. 2013 Jan;64:396–402.
   PubMed Web of Science ®Google Scholar
• Spohrs J, Ulrich M, Grön G, et al. FAAH polymorphism (rs324420) modulates extinction recall in healthy humans: an fMRI study. Eur Arch Psychiatry Clin Neurosci. 2022 2022 Dec 1;272(8):1495–1504. doi: 10.1007/s00406-021-01367-4
   PubMed Web of Science ®Google Scholar
• Spohrs J, Ulrich M, Grön G, et al. Fear extinction learning and anandamide: an fMRI study in healthy humans [article]. Transl Psychiatry. 2021;11(1). doi: 10.1038/s41398-020-01177-7
   PubMed Web of Science ®Google Scholar
• Dincheva I, Drysdale AT, Hartley CA, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015 Mar 3;6(1):6395. doi: 10.1038/ncomms7395
   PubMedGoogle Scholar
• Papini S, Ruglass LM, Lopez-Castro T, et al. Chronic cannabis use is associated with impaired fear extinction in humans. J Abnorm Psychol. 2017 Jan;126(1):117–124. doi: 10.1037/abn0000224
   PubMed Web of Science ®Google Scholar
• Das RK, Kamboj SK, Ramadas M, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacol (Berl). 2013 Apr;226(4):781–792. doi: 10.1007/s00213-012-2955-y
   PubMed Web of Science ®Google Scholar
• Klumpers F, Denys D, Kenemans JL, et al. Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans. J Psychopharmacol. 2012 Apr;26(4):471–478. doi: 10.1177/0269881111431624
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012 Jun;17(6):642–649. doi: 10.1038/mp.2011.82
   PubMed Web of Science ®Google Scholar
• Arnold J. A primer on medicinal cannabis safety and potential adverse effects. Aust J Gen Pract. 2021 May 26;50(6):345–350.
   PubMed Web of Science ®Google Scholar
• Pratt M, Stevens A, Thuku M, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev. 2019 2019 Dec 10;8(1):320. doi: 10.1186/s13643-019-1243-x
   PubMed Web of Science ®Google Scholar
• Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019 2019 Dec 1;269(1):87–105. doi: 10.1007/s00406-019-00984-4
   PubMed Web of Science ®Google Scholar
• Urits I, Charipova K, Gress K, et al. Adverse effects of recreational and medical cannabis. Psychopharmacol Bull. 2021 Jan 12;51(1):94–109.
   PubMedGoogle Scholar
• Lintzeris N, Mills L, Suraev A, et al. Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 online cross-sectional cannabis as Medicine survey (CAMS-18). Harm Reduct J. 2020 2020 Jun 8;17(1):37. doi: 10.1186/s12954-020-00377-0
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Driels J, Elias N, et al. Medicinal cannabis in Australia, 2016: the cannabis as Medicine survey (CAMS-16). Med j Aust. 2018 Aug 3;209(5):211–216. doi: 10.5694/mja17.01247
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Mills L, Abelev SV, et al. Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduct J. 2022 2022 Jul 30;19(1):88. doi: 10.1186/s12954-022-00666-w
   PubMed Web of Science ®Google Scholar
• Gottschling S, Ayonrinde O, Bhaskar A, et al. Safety considerations in cannabinoid-based Medicine. Int J Gen Med. 2020;13:1317–1333. doi: 10.2147/IJGM.S275049
   PubMed Web of Science ®Google Scholar
• Stella N. THC and CBD: similarities and differences between siblings. Neuron. 2023;111(3):302–327. doi: 10.1016/j.neuron.2022.12.022
   PubMed Web of Science ®Google Scholar
• DeVuono MV, Parker LA. Cannabinoid hyperemesis syndrome: a review of potential mechanisms. Cannabis Cannabinoid Res. 2020 Jun 1;5(2):132–144. doi: 10.1089/can.2019.0059
   PubMedGoogle Scholar
• Habboushe J, Rubin A, Liu H, et al. The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):660–662. doi: 10.1111/bcpt.12962
   PubMed Web of Science ®Google Scholar
• Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011 Dec;4(4):241–249. doi: 10.2174/1874473711104040241
   PubMedGoogle Scholar
• Jouanjus E, Lapeyre‐Mestre M, Micallef J, et al. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014;3(2):e000638. doi: 10.1161/JAHA.113.000638
   PubMed Web of Science ®Google Scholar
• DeFilippis EM, Bajaj NS, Singh A, et al. Marijuana use in patients with cardiovascular disease: JACC review topic of the Week. J Am Coll Cardiol. 2020 Jan 28;75(3):320–332. doi: 10.1016/j.jacc.2019.11.025
   PubMed Web of Science ®Google Scholar
• Pasha AK, Clements CY, Reynolds CA, et al. Cardiovascular Effects of Medical Marijuana: A Systematic Review. Am J Med. 2021 2021 Feb 1;134(2):182–193. doi: 10.1016/j.amjmed.2020.09.015
   PubMed Web of Science ®Google Scholar
• Hall W, Hoch E, Lorenzetti V. Cannabis use and mental health: risks and benefits.Eur Arch Psychiatry Clin Neurosci. 2019 2019 Feb 1;269(1):1–3. doi: 10.1007/s00406-019-00986-2
   PubMed Web of Science ®Google Scholar
• Lac A, Luk JW. Testing the amotivational syndrome: marijuana use longitudinally predicts lower self-efficacy even after controlling for demographics, personality, and Alcohol and cigarette use. Prev Sci. 2018 Feb;19(2):117–126. doi: 10.1007/s11121-017-0811-3
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184(2):110–117. doi: 10.1192/bjp.184.2.110
   PubMed Web of Science ®Google Scholar
• Grech A, Van Os J, Jones PB, et al. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005 Jun;20(4):349–353. doi: 10.1016/j.eurpsy.2004.09.013
   PubMed Web of Science ®Google Scholar
• Connor JP, Stjepanović D, Le Foll B, et al. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021 2021 Feb 25;7(1):16. doi: 10.1038/s41572-021-00247-4
   PubMed Web of Science ®Google Scholar
• Sarris J, Sinclair J, Karamacoska D, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020 2020 Jan 16;20(1):24. doi: 10.1186/s12888-019-2409-8
   PubMed Web of Science ®Google Scholar
• Arkell TR, Vinckenbosch F, Kevin RC, et al. Effect of Cannabidiol and Δ9-tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA. 2020;324(21):2177–2186. doi: 10.1001/jama.2020.21218
   PubMed Web of Science ®Google Scholar
• McCartney D, Arkell TR, Irwin C, et al. Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neuroscience & Biobehavioral Reviews. 2021 2021 Jul 1;126:175–193.
   PubMed Web of Science ®Google Scholar
• Arkell TR, McCartney D, McGregor IS. Medical cannabis and driving. Aust J Gen Pract. 2021 Jun;50(6):357–362. doi: 10.31128/AJGP-02-21-5840
   PubMed Web of Science ®Google Scholar
• Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology. 2019 2019 Sep 1;236(9):2713–2724. doi: 10.1007/s00213-019-05246-8
   PubMed Web of Science ®Google Scholar
• Brands B, Mann RE, Wickens CM, et al. Acute and residual effects of smoked cannabis: impact on driving speed and lateral control, heart rate, and self-reported drug effects. Drug Alcohol Dependence. 2019 2019 Dec 1;205:107641.
   PubMed Web of Science ®Google Scholar
• Russo EB. Current therapeutic cannabis controversies and clinical trial design issues [review]. Front Pharmacol. 2016;7(SEP). doi: 10.3389/fphar.2016.00309
   Google Scholar
• Zendulka O, Dovrtělová G, Nosková K, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17(3):206–226. doi: 10.2174/1389200217666151210142051
   PubMed Web of Science ®Google Scholar
• Stott C, White L, Wright S, et al. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013 Dec;2(1):236. doi: 10.1186/2193-1801-2-236
   PubMedGoogle Scholar
• McCauley JL, Killeen T, Gros DF, et al. Posttraumatic stress disorder and co-occurring substance use disorders: advances in assessment and treatment. Clinical Psychology: A Publication Of The Division. Clin Psychol Am Psychol Assoc. 2012;19(3):283–304. doi: 10.1111/cpsp.12006
   PubMedGoogle Scholar
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018 2018 Mar 1;49:12–19. doi: 10.1016/j.ejim.2018.01.004
   PubMed Web of Science ®Google Scholar
• Fischer AS, Tapert SF, Lee Louie D, et al. Cannabis and the developing adolescent Brain. Curr Treat Options Psychiatry. 2020 Jun;7(2):144–161. doi: 10.1007/s40501-020-00202-2
   PubMedGoogle Scholar
• Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacol (Berl). 2011 Jul;216(1):131–144. doi: 10.1007/s00213-011-2203-x
   PubMed Web of Science ®Google Scholar
• Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657–64. doi: 10.1073/pnas.1206820109
   PubMed Web of Science ®Google Scholar
• Jacobus J, Bava S, Cohen-Zion M, et al. Functional consequences of marijuana use in adolescents. Pharmacol Biochem Behav. 2009 Jun;92(4):559–565. doi: 10.1016/j.pbb.2009.04.001
   PubMed Web of Science ®Google Scholar
• Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178(2):116–122. doi: 10.1192/bjp.178.2.116
   PubMedGoogle Scholar
• Freeman D, Dunn G, Murray RM, et al. How cannabis causes paranoia: using the intravenous administration of ∆ 9 -tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull. 2015;41(2):391–399. doi: 10.1093/schbul/sbu098
   PubMed Web of Science ®Google Scholar
• Englund A, Oliver D, Chesney E, et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD: THC ratios. Neuropsychopharmacol. 2023 May;48(6):869–876. doi: 10.1038/s41386-022-01478-z
   PubMed Web of Science ®Google Scholar
• Calakos KC, Bhatt S, Foster DW, et al. Mechanisms underlying sex differences in cannabis use. Curr Addict Rep. 2017 Dec;4(4):439–453. doi: 10.1007/s40429-017-0174-7
   PubMedGoogle Scholar
• Tyndale RF, Payne JI, Gerber AL, et al. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in caucasians. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(5):660–666. doi: 10.1002/ajmg.b.30491
   PubMed Web of Science ®Google Scholar
• Campos DA, Mendivil EJ, Romano M, et al. A systematic review of medical cannabinoids dosing in human. Clin Ther. 2022 2022 Dec 1;44(12):e39–e58. doi: 10.1016/j.clinthera.2022.10.003
   PubMed Web of Science ®Google Scholar
• Zeraatkar D, Cooper MA, Agarwal A, et al. Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies. BMJ Open. 2022 Aug 4;12(8):e054282. doi: 10.1136/bmjopen-2021-054282
   PubMed Web of Science ®Google Scholar
• Schlag AK, Hindocha C, Zafar R, et al. Cannabis based medicines and cannabis dependence: a critical review of issues and evidence. J Psychopharmacol. 2021 2021 Jul 1;35(7):773–785. doi: 10.1177/0269881120986393
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” a practical review of cannabis safety considerations. Eur J Intern Med. 2021 2021 Jul 1;89.10–18. doi: 10.1016/j.ejim.2021.05.002
   PubMed Web of Science ®Google Scholar
• Ribeiro LI, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med. 2016 Oct 20;26(1):16071. doi: 10.1038/npjpcrm.2016.71
   PubMedGoogle Scholar
• Wieghorst A, Roessler KK, Hendricks O, et al. The effect of medical cannabis on cognitive functions: a systematic review. Syst Rev. 2022 2022 Oct 3;11(1):210. doi: 10.1186/s13643-022-02073-5
   PubMed Web of Science ®Google Scholar
• Kesner AJ, Lovinger DM. Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings [doi: 10.1111/jnc.15369]. J Neurochem. 2021;2021(6/01;157(5):1674–1696). doi: 10.1111/jnc.15369
   Google Scholar
• Haney M, Hart CL, Vosburg SK, et al. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2008 2008 Mar 1;197(1):157–168. doi: 10.1007/s00213-007-1020-8
   PubMed Web of Science ®Google Scholar
• Robinson T, Ali MU, Easterbrook B, et al. Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: a systematic review and meta-analysis. Drug Alcohol Dependence. 2022 2022 Sep 1; 238:109582. doi: 10.1016/j.drugalcdep.2022.109582
   PubMed Web of Science ®Google Scholar
• Leung J, Chan GCK, Hides L, et al. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addict Behav. 2020 Oct;109:106479.
   PubMed Web of Science ®Google Scholar
• Foa EB, Kozak MJ. Emotional processing: theory, research, and clinical implications for anxiety disorders. Emotion, psychotherapy, and change. (NY) NY US: The Guilford Press; 1991. p. 21–49.
   Google Scholar
• Jaycox LH, Foa EB. Obstacles in implementing exposure therapy for PTSD: case discussions and practical solutions. Clin Psychol Psychother. 1996;3(3):176–184. doi: 10.1002/(SICI)1099-0879(199609)3:3<176:AID-CPP100>3.0.CO;2-1
   Web of Science ®Google Scholar
• Olatunji BO, Deacon BJ, Abramowitz JS. The cruelest cure? Ethical issues in the implementation of exposure-based treatments.Cognit Behav Pract. 2009 2009 May 1;16(2):172–180. doi: 10.1016/j.cbpra.2008.07.003
   Web of Science ®Google Scholar
• Foa EB, Zoellner LA, Feeny NC, et al. Does imaginal exposure exacerbate PTSD symptoms? J Consult Clin Psychol. 2002 Aug;70(4):1022–1028. doi: 10.1037/0022-006X.70.4.1022
   PubMed Web of Science ®Google Scholar
• Mailloux S. The ethical imperative: special considerations in the trauma counseling process. Trauma Int J. 2014 Mar 01;20(1):50.
   Google Scholar
• Lewis C, Roberts NP, Gibson S, et al. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020 2020 Dec 31;11(1):1709709. doi: 10.1080/20008198.2019.1709709
   PubMed Web of Science ®Google Scholar
• Imel ZE, Laska K, Jakupcak M, et al. Meta-analysis of dropout in treatments for posttraumatic stress disorder. J Consult Clin Psychol. 2013;81(3):394–404. doi: 10.1037/a0031474
   PubMed Web of Science ®Google Scholar
• Belleau EL, Chin EG, Wanklyn SG, et al. Pre-treatment predictors of dropout from prolonged exposure therapy in patients with chronic posttraumatic stress disorder and comorbid substance use disorders. Behav Res Ther. 2017 Apr;91:43–50.
   PubMed Web of Science ®Google Scholar
• Foa EB, Gillihan SJ, Bryant RA. Challenges and successes in dissemination of evidence-based treatments for posttraumatic stress: lessons learned from prolonged exposure therapy for PTSD. Psychol Sci Public Interest. 2013 May;14(2):65–111. doi: 10.1177/1529100612468841
   PubMed Web of Science ®Google Scholar
• Farrell NR, Deacon BJ, Dixon LJ, et al. Theory-based training strategies for modifying practitioner concerns about exposure therapy. J Anxiety Disord. 2013 2013 Dec 1;27(8):781–787. doi: 10.1016/j.janxdis.2013.09.003
   PubMed Web of Science ®Google Scholar
• Deacon BJ, Farrell NR, Kemp JJ, et al. Assessing therapist reservations about exposure therapy for anxiety disorders: the therapist beliefs about exposure scale [article]. J Anxiety Disord. 2013;27(8):772–780. doi: 10.1016/j.janxdis.2013.04.006
   PubMed Web of Science ®Google Scholar
• Richard DCS, Gloster AT. Exposure therapy has a public relations problem: a dearth of litigation amid a wealth of concern. Handbook Of Exposure Therapies. 2007. 409–425.
   Google Scholar
• Zoellner LA, Feeny NC, Bittinger JN, et al. Teaching trauma-focused exposure therapy for PTSD: critical clinical lessons for novice exposure therapists. Psychological trauma: theory, research, practice and policy. Psychol Trauma Theory Res Prac Policy. 2011 Sep 1;3(3):300–308. doi: 10.1037/a0024642
   PubMed Web of Science ®Google Scholar
• Becker CB, Zayfert C, Anderson E. A survey of psychologists’ attitudes towards and utilization of exposure therapy for PTSD. Behav Res Ther. 2004 Mar;42(3):277–292. doi: 10.1016/S0005-7967(03)00138-4
   PubMed Web of Science ®Google Scholar
• van Minnen A, Harned MS, Zoellner L, et al. Examining potential contraindications for prolonged exposure therapy for PTSD. Eur J Psychotraumatol. 2012 2012 Dec 1;3(1):18805. doi: 10.3402/ejpt.v3i0.18805
   PubMed Web of Science ®Google Scholar
• Galatzer-Levy IR, Nickerson A, Litz BT, et al. PATTERNS OF LIFETIME PTSD COMORBIDITY: A LATENT CLASS ANALYSIS. Depress Anxiety. 2013;2013(5):489–496. doi: 10.1002/da.22048
   Google Scholar
• Brady KT, Killeen TK, Brewerton T, et al. Comorbidity of psychiatric disorders and posttraumatic stress disorder. J Clin Psychiatry. 2000;61 Suppl 7(Suppl 7):22–32.
   PubMedGoogle Scholar
• Bloomfield MAP, Ashok AH, Volkow ND, et al. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature. 2016 2016 Nov 1;539(7629):369–377. doi: 10.1038/nature20153
   PubMed Web of Science ®Google Scholar
• Casajuana Köguel C, López-Pelayo H, Balcells-Olivero MM, et al. Psychoactive constituents of cannabis and their clinical implications: a systematic review. Adicciones. 2018 Apr 15;30(2):140–151. doi: 10.20882/adicciones.858
   PubMed Web of Science ®Google Scholar
• Gobbi G, Atkin T, Zytynski T, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in Young adulthood: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76(4):426–434. doi: 10.1001/jamapsychiatry.2018.4500
   PubMed Web of Science ®Google Scholar
• Walsh Z, Gonzalez R, Crosby K, et al. Medical cannabis and mental health: a guided systematic review [review]. Clin Psychol Rev. 2017;51:15–29. doi: 10.1016/j.cpr.2016.10.002
   PubMed Web of Science ®Google Scholar
• Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions [review]. J Addict Med. 2011;5(1):1–8. doi: 10.1097/ADM.0b013e31820c23fa
   PubMed Web of Science ®Google Scholar
• Eadie L, Lo LA, Christiansen A, et al. Duration of neurocognitive impairment with medical cannabis use: a scoping review. Front Psychiatry. 2021;12:638962. doi: 10.3389/fpsyt.2021.638962
   PubMed Web of Science ®Google Scholar
• Gruber SA, Rogowska J, Yurgelun-Todd DA. Altered affective response in marijuana smokers: an FMRI study. Drug Alcohol Depend. 2009 Nov 1;105(1–2):139–153. doi: 10.1016/j.drugalcdep.2009.06.019
   PubMed Web of Science ®Google Scholar
• Morena M, Berardi A, Colucci P, et al. Enhancing endocannabinoid neurotransmission augments the efficacy of extinction training and ameliorates traumatic stress-induced behavioral alterations in rats. Neuropsychopharmacology: official publication of the American college of Neuropsychopharmacology. 2018;43(6):1284–1296. doi: 10.1038/npp.2017.305
   Google Scholar
• Morena M, Campolongo P. The endocannabinoid system: an emotional buffer in the modulation of memory function. Neurobiol Learn Mem. 2014 Jul;112:30–43. doi: 10.1016/j.nlm.2013.12.010
   PubMed Web of Science ®Google Scholar
• van Ree JM, Niesink RJ, Nir I. Delta 1-tetrahydrocannabinol but not cannabidiol reduces contact and aggressive behavior of rats tested in dyadic encounters. Psychopharmacol (Berl). 1984;84(4):561–565. doi: 10.1007/BF00431467
   PubMed Web of Science ®Google Scholar
• Rahm-Knigge RL, Prince MA, Conner BT. Clarifying the relation between social interaction anxiety and cannabis use: personality as a distinguishing factor.Substance Use & Misuse. 2019 2019 Oct 15;54(12):2001–2012. doi: 10.1080/10826084.2019.1626431.
   PubMed Web of Science ®Google Scholar
• Genn RF, Tucci S, Marco EM, et al. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol Biochem Behav. 2004 Mar;77(3):567–573. doi: 10.1016/j.pbb.2003.12.019
   PubMed Web of Science ®Google Scholar
• Trezza V, Vanderschuren LJ. Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacol (Berl). 2008 Apr;197(2):217–227. doi: 10.1007/s00213-007-1025-3
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–297. doi: 10.1001/jamapsychiatry.2015.3278
   PubMed Web of Science ®Google Scholar
• Pacheco-Colón I, Limia JM, Gonzalez R. Nonacute effects of cannabis use on motivation and reward sensitivity in humans: a systematic review. Psychol Addict Behav. 2018;32(5):497–507. doi: 10.1037/adb0000380
   PubMed Web of Science ®Google Scholar
• Petrucci AS, LaFrance EM, Cuttler C. A comprehensive examination of the links between cannabis use and motivation.Substance Use & Misuse. 2020 2020 Apr 15;55(7):1155–1164. doi: 10.1080/10826084.2020.1729203
   PubMed Web of Science ®Google Scholar
• Kevorkian S, Bonn-Miller MO, Belendiuk K, et al. Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample. Psychol Addict Behav. 2015 Sep;29(3):633–638. doi: 10.1037/adb0000110
   PubMed Web of Science ®Google Scholar
• Ruglass LM, Lopez-Castro T, Papini S, et al. Concurrent treatment with prolonged exposure for co-occurring full or subthreshold posttraumatic stress disorder and substance use disorders: a randomized clinical trial. Psychother Psychosom. 2017;86(3):150–161. doi: 10.1159/000462977
   PubMed Web of Science ®Google Scholar
• Killeen TK, Back SE, Brady KT. The use of exposure-based treatment among individuals with PTSD and co-occurring substance use disorders: clinical considerations. J Dual Diagn. 2011 Oct 1;7(4):194–206. doi: 10.1080/15504263.2011.620421
   PubMed Web of Science ®Google Scholar
• Blakey SM, Kirby AC, McClure KE, et al. Posttraumatic safety behaviors: characteristics and associations with symptom severity in two samples. Traumatology. 2020;26(1):74–83. doi: 10.1037/trm0000205
   Google Scholar
• Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–1391. doi: 10.1016/S0140-6736(09)61037-0
   PubMed Web of Science ®Google Scholar
• Guttmannova K, Kosterman R, White HR, et al. The association between regular marijuana use and adult mental health outcomes. Drug Alcohol Dependence. 2017 2017 OCt 1;179:109–116.
   PubMed Web of Science ®Google Scholar
• Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–328. doi: 10.1016/S0140-6736(07)61162-3
   PubMed Web of Science ®Google Scholar
• Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015 Oct;12(4):825–836. doi: 10.1007/s13311-015-0387-1
   PubMed Web of Science ®Google Scholar
• Skelley JW, Deas CM, Curren Z, et al. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc. 2020 2020 Jan 1;60(1):253–261. doi: 10.1016/j.japh.2019.11.008
   Google Scholar
• Pennypacker SD, Romero-Sandoval EA. CBD and THC: do they complement each other like Yin and Yang?Pharmacother J Human Pharmacol Drug Ther. 2020 2020 Nov 1;40(11):1152–1165. doi: 10.1002/phar.2469
   Google Scholar
• Niesink RJM, van Laar M. Does Cannabidiol protect against adverse Psychological effects of THC? [review]. Front Psychiatry. 2013 2013 Oct 16;4:4. doi: 10.3389/fpsyt.2013.00130
   PubMedGoogle Scholar
• Iyadurai L, Blackwell SE, Meiser-Stedman R, et al. Preventing intrusive memories after trauma via a brief intervention involving tetris computer game play in the emergency department: a proof-of-concept randomized controlled trial. Mol Psychiatry. 2018;23(3):674–682. doi: 10.1038/mp.2017.23
   PubMed Web of Science ®Google Scholar
• Holmes EA, James EL, Coode-Bate T, et al. Can playing the computer game “tetris” reduce the build-up of flashbacks for trauma? A proposal from cognitive science. PLoS One. 2009;4(1):e4153. doi: 10.1371/journal.pone.0004153
   PubMed Web of Science ®Google Scholar
• James EL, Lau-Zhu A, Clark IA, et al. The trauma film paradigm as an experimental psychopathology model of psychological trauma: intrusive memories and beyond. Clin Psychol Rev. 2016 Jul;47:106–142.
   PubMed Web of Science ®Google Scholar
• Perkonigg A, Goodwin RD, Fiedler A, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction. 2008 Mar;103(3):439–449. discussion 450-1. doi: 10.1111/j.1360-0443.2007.02064.x
   PubMed Web of Science ®Google Scholar